Gratus Capital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $2.39M | Buy |
13,912
+1,290
| +10% | +$214K | 0.1% | 133 |
|
|
2024
Q1 | $2.3M | Buy |
12,622
+1,427
| +13% | +$246K | 0.11% | 126 |
|
|
2023
Q4 | $1.73M | Buy |
11,195
+5,696
| +104% | +$830K | 0.1% | 125 |
|
|
2023
Q3 | $820K | Sell |
5,499
-2,802
| -34% | -$411K | 0.06% | 147 |
|
|
2023
Q2 | $1.12M | Sell |
8,301
-107,370
| -93% | -$15.7M | 0.08% | 131 |
|
|
2023
Q1 | $18.4M | Sell |
115,671
-3,607
| -3% | -$551K | 1.41% | 15 |
|
|
2022
Q4 | $19.3M | Sell |
119,278
-33,376
| -22% | -$5.12M | 1.58% | 13 |
|
|
2022
Q3 | $20.5M | Buy |
152,654
+17,017
| +13% | +$2.44M | 2.17% | 5 |
|
|
2022
Q2 | $20.8M | Buy |
135,637
+9,512
| +8% | +$1.45M | 2.33% | 6 |
|
|
2022
Q1 | $20.4M | Buy |
126,125
+5,654
| +5% | +$821K | 1.96% | 10 |
|
|
2021
Q4 | $16.3M | Buy |
120,471
+4,889
| +4% | +$578K | 1.51% | 17 |
|
|
2021
Q3 | $12.5M | Buy |
115,582
+17,667
| +18% | +$2.02M | 1.34% | 24 |
|
|
2021
Q2 | $11M | Buy |
97,915
+9,851
| +11% | +$1.11M | 1.22% | 26 |
|
|
2021
Q1 | $9.53M | Buy |
88,064
+9,581
| +12% | +$1.02M | 1.14% | 27 |
|
|
2020
Q4 | $8.41M | Buy |
78,483
+3,485
| +5% | +$335K | 1.13% | 38 |
|
|
2020
Q3 | $6.57M | Sell |
74,998
-4,400
| -6% | -$414K | 1.03% | 42 |
|
|
2020
Q2 | $7.79M | Sell |
79,398
-18,442
| -19% | -$1.62M | 1.31% | 29 |
|
|
2020
Q1 | $7.45M | Buy |
97,840
+9,931
| +11% | +$846K | 1.39% | 20 |
|
|
2019
Q4 | $7.78M | Buy |
87,909
+1,295
| +1% | +$108K | 1.18% | 30 |
|
|
2019
Q3 | $6.56M | Buy |
86,614
+5,732
| +7% | +$393K | 1.07% | 32 |
|
|
2019
Q2 | $5.88M | Buy |
80,882
+22,877
| +39% | +$1.8M | 0.96% | 44 |
|
|
2019
Q1 | $4.67M | Sell |
58,005
-27,262
| -32% | -$2.23M | 0.78% | 51 |
|
|
2018
Q4 | $7.86M | Sell |
85,267
-125
| -0.1% | -$11K | 1.61% | 15 |
|
|
2018
Q3 | $8.08M | Buy |
85,392
+2,691
| +3% | +$255K | 1.11% | 19 |
|
|
2018
Q2 | $7.66M | Buy |
82,701
+2,178
| +3% | +$213K | 1.14% | 16 |
|
|
2018
Q1 | $7.62M | Sell |
80,523
-11,602
| -13% | -$1.27M | 1.1% | 18 |
|
|
2017
Q4 | $8.91M | Buy |
92,125
+10,109
| +12% | +$953K | 1.16% | 18 |
|
|
2017
Q3 | $7.29M | Buy |
82,016
+6,298
| +8% | +$479K | 1.01% | 22 |
|
|
2017
Q2 | $5.49M | Buy |
+75,718
| New | +$5.09M | 0.78% | 31 |
|
|
2016
Q2 | – | Sell |
-111,437
| Closed | -$6.37M | – | 178 |
|
|
2016
Q1 | $6.37M | Buy |
111,437
+7,821
| +8% | +$436K | 1.4% | 23 |
|
|
2015
Q4 | $6.14M | Buy |
103,616
+21,197
| +26% | +$1.22M | 1.4% | 13 |
|
|
2015
Q3 | $4.48M | Sell |
82,419
-3,385
| -4% | -$220K | 1.08% | 22 |
|
|
2015
Q2 | $5.76M | Buy |
85,804
+697
| +0.8% | +$45.5K | 1.34% | 11 |
|
|
2015
Q1 | $4.98M | Buy |
+85,107
| New | +$5.14M | 1.11% | 24 |
|
Other funds holding ABBV
Gratus Capital's ABBV Position: Q2 2024 in Review
Gratus Capital increased its AbbVie (ABBV) stake by 10% in Q2 2024, buying an estimated $214K and bringing the position to 13,912 shares worth $2.39M. The position accounts for 0.1% of the portfolio, ranked #133.
Gratus Capital first reported a position in ABBV in Q1 2015 and has held it in 34 quarters since. The position peaked at $20.8M in Q2 2022. 3,364 funds tracked by Wall St. Rank hold ABBV as of Q2 2024.
- Gratus Capital held 13,912 shares of AbbVie worth $2.39M as of Q2 2024.
- Gratus Capital bought 1,290 AbbVie shares in Q2 2024, an estimated $214K.
- AbbVie made up 0.1% of Gratus Capital's portfolio in Q2 2024, its #133 holding.
- Gratus Capital first reported a position in AbbVie in Q1 2015 and has held it in 34 quarters since.
- Gratus Capital's AbbVie position peaked at $20.8M in Q2 2022.
- 3,364 funds tracked by Wall St. Rank held AbbVie as of Q2 2024.
Based on Gratus Capital's 13F filing for Q2 2024, filed 25 Jul 2024.